Biotech stocks have sold off over the last couple of months leaving lots of traders hunting for the best biotech stocks to buy. The world of biotechnology is booming and the potential for investors is massive. Biotech stocks are soaring, and the benefits for investors are huge. With the right stocks, investors can maximize their potential for returns. So how do you find the best biotech stocks with maximum potential? Read on to find out!
What’s So Special About Biotech Stocks?
Biotech stocks represent massive growth potential for investors. With advances in medical technology, biotech firms can develop innovative treatments and diagnostic products, leading to incredible returns. Biotech firms also benefit from immense R&D spending in the form of government grants, venture capital, and private investments.
The biotech industry is also well-regulated, with stringent clinical trials and regulatory requirements. This ensures that the products and treatments developed are safe and effective. Furthermore, the biotech industry is notoriously resilient, with stocks rarely affected by macroeconomic downturns.
Investors have many choices when it comes to biotechnology stocks. The sector can be divided into a few different categories: medical devices, diagnostics, therapeutics, and agricultural biotechnology.
Medical device stocks include companies that make everything from heart valves to contact lenses. Diagnostics companies make the tests that doctors use to figure out what’s wrong with their patients. Therapeutics firms develop new drugs to treat diseases. And agricultural biotechnology companies work on improving the yield and nutritional content of crops.
There are a lot of things to consider when picking the best biotech stock. Let’s take a look at some of the most important factors.
Investment priorities
One of the first things to consider is an investor’s priorities. Some people are looking for high-growth stocks that will shoot up in value. Others are more interested in stable, dividend-paying stocks.
There are high-growth stocks in the biotech sector, but they’re not for everyone. They can be quite risky, and the stock prices can swing wildly. For investors who are comfortable with a little more risk, there are plenty of opportunities to make a lot of money.
But for those who are looking for stability, there are also a number of biotech firms that pay healthy dividends. These stocks may not have the same upside potential as the high-growth stocks, but they’re a lot less risky.
Research and development
The most important factor in finding the best biotech stocks is the company’s research and development pipeline. This is the list of drugs and medical devices that the company is working on.
Companies that are doing a lot of research and development tend to be the most exciting to invest in. That’s because they have the potential to introduce new products that could revolutionize the industry.
But it’s important to remember that not all of these products will make it to market. A lot of them will fail in clinical trials. So it’s important to look at the success rate of the company’s R&D pipeline.
Financial stability
Another important factor to consider is the financial stability of the company. What seems like one of the best biotech stocks today, could be bankrupt tomorrow. Biotech firms can be very risky investments, and it’s important to make sure that the company is in a good position to weather a downturn.
You can check this by looking at the company’s balance sheetThe balance sheet is a snapshot of a company's financial position at a specific point in time. It shows the company's assets, liabilities, and equity. and income statementThe income statement provides a summary of a company's revenue and expenses over a specified period of time, typically a year or a quarter. It shows the company's total revenue, th.... You want to make sure that the company has a strong balance sheet so that it can continue to invest in new products. And you want to make sure that the company is profitable so that it can continue to pay dividends.
Market position
Another important factor to consider is the company’s market position. This can be difficult to assess, but it’s important to look at the company’s competitive position.
You want to make sure that the company has a strong position in its market. You also want to make sure that the company has a good product pipeline. This is the list of products that the company is working on.
You can also look at the company’s competitive dynamics. This is the competitive landscape in the industry. You want to make sure that the company has a good competitive position so that it can succeed in the market.
Valuation
One of the most important factors to consider when investing in a biotech stock is the valuation. This is how much the stock is worth relative to the company’s earnings.
You want to make sure that the stock is not overvalued. This means that the stock is trading at a price that is too high relative to the company’s earnings.
You can assess the valuation by looking at the price to earnings ratio. This is the price of the stock divided by the company’s earnings. You want to make sure that the ratio is not too high.
Investment style
Another important factor to consider is the investor’s investment style. Some investors are growth investors. They’re looking for the best biotech stocks that will shoot up in value. Other investors are value investors. They’re looking for the best value biotech stocks that are trading at a low price relative to the company’s earnings.
It’s important to find a biotech stock that matches the investor’s investment style. This will help ensure that the investor is comfortable with the stock.
Diversification
Another important factor to consider when investing in biotech stocks is diversification. This is the practice of investing in a number of different stocks so that the investor is not too exposed to any one stock.
It’s important to diversify so that the investor is not taking too much risk. This is especially important when investing in biotech stocks. These stocks can be quite risky, and it’s important to spread the risk among a number of different stocks.
ETFs
One way to invest in biotech stocks is to buy an ETF. This is a fund that buys a basket of stocks. Often you can find the best biotech stocks as the largest holdings in a biotech ETF! This is a good way to diversify your investment and to reduce your risk.
There are a number of biotech ETFs available. You can find a list of ETFs on the web.
10 Best Biotech Stocks
What are the best biotech stocks to buy? Here is our list of the 8 best biotech stocks. We purposely are leaving out the biotech firms tied to COVID-19 experimental mRNA shots as we believe massive lawsuits and negative Wall Street actions are coming soon against these biotechnology corporations.
AbbVie (ABBV)
Pharmaceuticals are discovered, developed, produced, and sold by AbbVie all over the world. The company offers HUMIRA, an injection-based treatment for autoimmune and intestinal Behcet’s diseases, SKYRIZI, a JAK inhibitor for the treatment of moderate-to-severe active rheumatoid arthritis in adult patients, RINVOQ, a JAK inhibitor for the treatment of chronic lymphocytic leukemia in adults, SLL, and IMBRUVICA, a BCL-2 inhibitor for the treatment of adults with CLL or S. Additionally, it offers CREON, a pancreatic enzyme therapy used to treat exocrine pancreatic insufficiency, Synthroid, a medication used to treat hypothyroidism, Linzess/Constella, a medication used to treat chronic idiopathic constipation and irritable bowel syndrome with constipation, Lupron, a medication used to treat advanced prostate cancer, endometriosis, and central precocious pubert. The company also provides Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension, and Ubrelvy to treat migraines with or without aura in people who have Parkinson’s disease.
Regeneron Pharmaceuticals (REGN)
For the treatment of numerous diseases worldwide, Regeneron Pharmaceuticals discovers, develops, manufactures, and markets pharmaceuticals. The company sells EYLEA injection to treat diabetic macular edema and wet age-related macular degeneration, myopic choroidal neovascularization, diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. Additionally, it offers Libtayo injection for treating metastatic or locally advanced cutaneous squamous cell carcinoma, Praluent injection for treating heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults, REGEN-COV for treating covid-19, and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the business provides Inmazeb injection for Zaire ebolavirus infection, ARCALYST injection for cryopyrin-associated periodic syndromes, such as familial cold auto-inflammatory syndrome and muckle-wells syndrome, and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. It also creates product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases, as well as eye, allergic, and inflammatory. It also has agreements with the US Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. Sanofi, Bayer, Teva Pharmaceutical, Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Roche Pharmaceuticals, and Kiniksa Pharmaceuticals are partners and/or licensees.
Genmab A/S (GMAB)
In Denmark, primarily, Genmab develops therapeutic antibodies for the treatment of cancer and other diseases. The business sells ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL), multiple sclerosis, and advanced or metastatic gastric or esophageal cancer, as well as amivantamab for NSCLC and multiple myeloma patients. The company also sells DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM), Daratumumab, which is used to treat multiple myeloma, non-MM blood cancers, and AL amyloidosis, GEN1047, tisotumab vedotin, which is used to treat cervical, ovarian, and solid cancers, DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB, which are used to treat solid tumors, Epcoritamab. The company also creates products that are currently in Phase 2. These products include Teclistamab for vaso-occlusive crises, Camidanlumab tesirine for solid tumors and hodgkin lymphoma, JNJ-64007957 and JNJ-64407564 for MM, PRV-015 for celiac disease, Mim8 for hemophilia A, and Lu AF82422 for multiple system atrophy disease. There are also about 20 pre-clinical programs that are currently active. With Seagen Inc., the business has a commercial license and collaboration agreement. create tisotumab vedotin together. Additionally, it has collaboration agreements with CureVac AG for the study and creation of differentiated mRNA-based antibody products, AbbVie for the creation of epcoritamab, BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics.
Royalty Pharma (RPRX)
In the US, Royalty Pharma works as a funder of biopharmaceutical industry innovations as well as a buyer of biopharmaceutical royalties. It also takes part in the search for, assessment of, and acquisition of royalties on various biopharmaceutical treatments. Additionally, the business partners with researchers from academic institutions, research hospitals, non-profit organizations, small and mid-cap biotechnology firms, and pharmaceutical firms. Its portfolio includes royalties from 10 product candidates in the development stage and royalties from approximately 35 marketed therapies that treat conditions such as diabetes, cancer, neurology, infectious disease, hematology, and rare diseases.
Agilent Technologies (A)
Agilent Technologies serves the global markets for applied chemicals, life sciences, and diagnostics with application-focused solutions. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components, liquid chromatography mass spectrometry systems, gas chromatography systems and components, gas chromatography mass spectrometry systems, inductively coupled plasma mass spectrometry instruments, atomic absorption instruments, microwave plasma-atomic emission spectrometry instruments, inductively coupled plasma optical emission spectrometry instruments, and raman spectroscopy; The Diagnostics and Genomics segment makes synthetic oligonucleotides and offers arrays for DNA mutation detection, genotyping, determining gene copy number, identifying gene rearrangements, DNA methylation profiling, gene expression profiling, next-generation sequencing, target enrichment, genetic data management, and interpretation support software. Additionally, it provides consumables, software, and reagents for use in turbidimetry, flow cytometry, and special staining; immunohistochemistry in situ hybridization; hematoxylin and eosin staining; and immunohistochemistry; in addition, it develops liquid-based pharmacodiagnostics.
Novo Nordisk (NVO)
A healthcare organization called Novo Nordisk is involved in the worldwide development, production, and marketing of pharmaceutical products. It has two business divisions: biopharma and diabetes and obesity care. Insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases are all covered by the diabetes and obesity care segment’s product offerings. Products for hemophilia, growth disorders, and hormone replacement therapy are available from the biopharmaceuticals segment. In addition to its business partnerships with Gilead Sciences and Lumen Bioscience, Novo Nordisk A/S is investigating delivery methods for oral biologics for cardiometabolic disease.
Merck (MRK)
Healthcare is one of Merck’s main business sectors. Animal Health and Pharmaceutical are its two business segments. The pharmaceutical segment provides pharmaceuticals for human health in the fields of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccines for children, adolescents, and adults that are preventive. Discovered, developed, produced, and marketed by the Animal Health segment are veterinary pharmaceuticals, vaccines, health management products and services, as well as products for digitally connected identification, traceability, and monitoring. It provides services to hospitals, government organizations, drug wholesalers and retailers, physicians and physician distributors, veterinarians, and animal producers, as well as managed health care organizations, pharmacy benefit managers, and other institutions.
Eli Lilly (LLY)
Human pharmaceuticals are discovered, created, and sold all over the world by Eli Lilly and Company. It provides Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes as well as Jardiance, Trajenta, and Trulicity. The business offers Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma, Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma, Erbitux for colorectal cancers, and different head and neck cancers, Retevmo for metastatic NSC. For rheumatoid arthritis, it offers Olumiant; for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis, it offers Taltz. In addition to Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance, the company also offers Emgality for migraine prevention and episodic cluster headaches, Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain, and Emgality for migraine prevention. It includes Bamlanivimab, etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The business has partnerships with the Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, AbCellera Biologics, Junshi Biosciences, Regor Therapeutics Group, Lycia Therapeutics, Kumquat Biosciences, Entos Pharmaceuticals, and Foghorn Therapeutics.
Vertex Pharmaceuticals (VRTX)
A biotechnology company called Vertex Pharmaceuticals Incorporated is involved in the research, development, and marketing of cystic fibrosis therapies. The company sells SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat cystic fibrosis patients who have particular mutations in their cystic fibrosis transmembrane conductance regulator gene, as well as TRIKAFTA to treat CF patients aged 6 years or older who have at least one F508del mutation. Its pipeline includes CTX001 f, a NaV1.8 inhibitor for the treatment of acute, neuropathic, musculoskeletal pain, VX-548, a NaV1.8 inhibitor for the treatment of AAT deficiency, and VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases. These treatments are all in Phase 2 clinical trials. The company primarily sells its products to specialty pharmacies and specialty distributors in the United States, as well as specialty distributors, retail chains, hospitals, and clinics abroad.
Bio-Techne (TECH)
Together with its subsidiaries, Bio-Techne Corporation creates, produces, and markets reagents, tools, and services for the life sciences industry for use in research and clinical diagnostics on a global scale. Protein Sciences and Diagnostics and Genomics make up the company’s two business segments. The Protein Sciences division creates and manufactures biological reagents like antibodies, small molecules, tissue culture sera, cytokines and growth factors, as well as cell selection technologies, that are used in various aspects of life science research, diagnostics, and cell and gene therapy. This section also provides multiplexed ELISA workflow, automated western blot workflow, and proteomic analytical tools for use in quantifying proteins in various biological fluids. These tools include both manual and automated protein analysis tools, as well as immunoassays. The Diagnostics and Genomics segment creates and produces diagnostic products, such as exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; it also sells products for genetic carrier screening, oncology diagnostics, molecular controls, and other related services. It sells its goods under the names RandD Systems, Tocris Biosciences, Novus Biologicals, ProteinSimple, Advanced Cell Diagnostics, Exosome Diagnostics, and Asuragen.
Frequently Asked Questions
What is the number 1 biotech stock?
What is the hottest biotech stock?
Are biotech stocks a good buy now?
What are the top biotech ETFs?
What is the best way to invest in biotech stocks?
What are the most important factors to consider when investing in a biotech stock?
